Literature DB >> 2887952

Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry.

H Bismuth, D Castaing, B G Ericzon, J B Otte, K Rolles, B Ringe, M Sloof.   

Abstract

At the 32 European centres where livers are transplanted the actuarial survival rate for 1218 patients was 44% at 1 year and 41% at 2 years. Perioperative mortality (30 days) was 30%. Recipients aged under 15 years had a higher survival rate than those aged over 15; the differences were 22% at 1 year and 32% at 2 years. For the 97 patients who received two or more liver grafts, actuarial survival was 27.7% at 1 and 2 years. Two-thirds of the transplantations were done since 1984. Since then the best results have been obtained for biliary atresia (88 cases; survival rates at 30 days, 1 year, and 2 years were 87%, 74%, and 68%). Primary biliary cirrhosis was the commonest benign indication for transplantation, with survival of 64% at 1 and 2 years. The proportion of transplantations that were done for patients with hepatocellular carcinoma was smaller after than before 1984; among transplantations done in adults after 1984, those done because of hepatocellular carcinoma gave the best perioperative survival rate (76%) but the worst 2 year survival (30.8%).

Entities:  

Mesh:

Year:  1987        PMID: 2887952     DOI: 10.1016/s0140-6736(87)92453-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats.

Authors:  T Matsuzaki; N Murase; A Yagihashi; H Shinozuka; Y Shimizu; T Furuya; N Burrell; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1992-04       Impact factor: 1.066

2.  Liver transplantation for alcoholic liver disease, viral hepatitis, and hepatic neoplasms.

Authors:  D H Van Thiel; B Carr; S Iwatsuki; A Tzakis; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

Review 3.  Reducing transfusion requirements in liver transplantation.

Authors:  Ciara I Donohue; Susan V Mallett
Journal:  World J Transplant       Date:  2015-12-24

4.  Metabolic effects of liver transplantation in cirrhotic patients.

Authors:  L Luzi; G Perseghin; E Regalia; L P Sereni; A Battezzati; D Baratti; E Bianchi; I Terruzzi; H Hilden; L C Groop; A Pulvirenti; M R Taskinen; L Gennari; V Mazzaferro
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

5.  Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses.

Authors:  U Persson; G R Tennvall; S Andersson; G Tyden; B Wettermark
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

Review 6.  Liver transplantation and primary biliary cirrhosis.

Authors:  A K Burroughs; M Biagini; P A McCormick; K Rolles
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

7.  Unusually rapid development of a HBsAG-positive liver cirrhosis after liver transplantation.

Authors:  H U Lautz; R Müller; C Wittekind; S Mauz; H Barg-Hock; B Ringe; R Pichlmayr; F W Schmidt
Journal:  Klin Wochenschr       Date:  1989-10-17

8.  Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period.

Authors:  Douglas G Farmer; Dean M Anselmo; R Mark Ghobrial; Hasan Yersiz; Suzanne V McDiarmid; Carlos Cao; Michael Weaver; Jesus Figueroa; Khurram Khan; Jorge Vargas; Sammy Saab; Steven Han; Francisco Durazo; Leonard Goldstein; Curtis Holt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

Review 9.  Liver transplantation for hepatocellular carcinoma: clinical results and future aspects.

Authors:  R Pichlmayr; A Weimann; G Steinhoff; B Ringe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis.

Authors:  S P Fussey; J R Guest; O F James; M F Bassendine; S J Yeaman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.